Sickle Cell Anemia Breakthrough: Targeting HbS, HbF, and Oxygenation with Next-Gen Carriers
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”HbS, HbF and Oxygenation in Sickle Cell Disease: A New Playbook With BHOC
HbS = The Saboteur
A single mutation → sickled cells → blocked vessels → pain and tissue damage. Severity is directly proportional to HbS levels.
HbF = The Natural Defender
Keep HbF above 20–30% and sickling is suppressed at the molecular level. Fewer crises, less cumulative organ damage.
Oxygenation = The Silent Hero
HbS polymerizes only when deoxygenated. Stabilizing oxygenated HbS—as voxelotor attempts—reduces sickling. Sustainable, side-effect-free approaches are still needed.
BHOCs = The Game Changer
Next-generation Blood Hemoglobin-Based Oxygen Carriers (BHOCs) deliver oxygen precisely where it’s needed—intervening before polymerization occurs.
Clinical evidence is still developing, but the concept is scientifically sound. Properly designed trials are key.
About future possibility
- BHOC can serve as a bridge to recovery. We believe it can transform the approach to Sickle Cell Anemia (SCA) treatment by providing supportive, low-volume infusion therapy before HbS levels become critical.
Much like insulin regulates blood sugar and HbA1c levels, BHOC can help support and control HbS polymerization levels, stabilizing oxygen delivery and patient condition.
Call to Action
- Stop just managing crises. Start preventing them. Let’s explore early warning systems integrating:
SaO₂, PaO₂, CaO₂, Hb, HbS polymerization levels — measurable with existing devices. Let’s act before the crisis hits.
Contact us for collaboration or discussion about clinical applications and partnerships.
Stay informed with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS